The prostate is a walnut-sized gland located below the bladder and in front of the rectum, surrounding the urethra. It produces seminal fluid that nourishes and transports sperm. Prostate conditions become increasingly common with age and include benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer.

The prostate gland plays a key role in male reproductive function. Prostate disorders include prostatitis, BPH, and prostate cancer. Source: Unsplash.

Benign Prostatic Hyperplasia

BPH is non-malignant enlargement of the prostate due to hyperplasia of stromal and glandular elements. It affects 50% of men by age 60 and 90% by age 85. Dihydrotestosterone (DHT) drives prostate growth in the transition zone, where the gland surrounds the urethra. Physical compression of the urethra combined with increased smooth muscle tone (alpha-adrenergic) produces lower urinary tract symptoms.

Symptoms

Lower urinary tract symptoms (LUTS) from BPH fall into three categories. Storage symptoms include urinary frequency (daytime), nocturia (waking to urinate), urgency, and urge incontinence. Voiding symptoms include hesitancy (difficulty starting), weak urinary stream, intermittency (stop-start flow), and straining to void. Post-void symptoms include sensation of incomplete emptying and post-void dribbling.

AUA Symptom Score

The International Prostate Symptom Score quantifies symptom severity. Seven questions cover incomplete emptying, frequency (less than 2 hours), intermittency, urgency, weak stream, straining, and nocturia. Each is scored 0 (not at all) to 5 (almost always). Total score 0-7 indicates mild symptoms, 8-19 moderate, and 20-35 severe.

Evaluation

Initial evaluation includes a history with the AUA symptom score, digital rectal exam (DRE) to assess prostate size and consistency, urinalysis to rule out infection or hematuria, and a PSA test with shared decision-making. Post-void residual measurement assesses urinary retention (greater than 100-150 mL abnormal). Uroflowmetry measures peak flow rate (Qmax less than 10-15 mL/s suggests obstruction). Cystoscopy is reserved for complex cases or before minimally invasive therapy.

⚠ Clinical Correlation

Prostate size influences treatment selection. Small prostates (under 30 mL) may respond well to alpha blockers alone. Moderate prostates (30-80 mL) are candidates for medical therapy, including combination therapy with an alpha blocker plus a 5-alpha-reductase inhibitor (5-ARI), or minimally invasive procedures such as UroLift or Rezum. Large prostates (over 80-100 mL) may require surgical intervention such as holmium laser enucleation (HoLEP) or open/robotic simple prostatectomy. The 5-ARIs (finasteride, dutasteride) reduce prostate volume by 20-30% and work best in larger prostates.

Medical Treatment

First-line medical therapy includes alpha-1 blockers (tamsulosin, alfuzosin, doxazosin, terazosin, silodosin), which relax prostatic smooth muscle. They produce a 4-6 point AUA score reduction within 2-4 weeks. Side effects include dizziness, orthostatic hypotension (especially with doxazosin and terazosin), retrograde ejaculation (with tamsulosin and silodosin), and rhinitis.

5-alpha-reductase inhibitors (finasteride, dutasteride) inhibit conversion of testosterone to DHT, reducing prostate size by 20-30%. They produce a 3-4 point AUA score reduction but take 3-6 months to work. Side effects include decreased libido (5%), erectile dysfunction (8%), decreased ejaculate volume (4%), and gynecomastia (1%).

Combination therapy with an alpha blocker plus a 5-ARI provides greater symptom improvement than either agent alone. Tadalafil (Cialis) 5 mg daily is a PDE5 inhibitor option that relaxes detrusor, prostatic, and urethral smooth muscle, providing a 2-3 point AUA score reduction.

Minimally Invasive and Surgical Treatment

Transurethral resection of the prostate (TURP) remains the gold standard for moderate to large prostates (30-100 mL). It is durable for 10+ years but carries risks of bleeding, TUR syndrome (hyponatremia from absorption of irrigation fluid), and retrograde ejaculation (65-75%). Holmium laser enucleation (HoLEP) works for prostates of all sizes, including those over 100 mL, with less bleeding and shorter catheter time. Photoselective vaporization (PVP, GreenLight) is appropriate for moderate prostates and anticoagulated patients. UroLift uses permanent implants to retract prostatic lobes, preserving ejaculatory function, but is less durable and not suitable for very large prostates or significant median lobe. Rezum uses convective water vapor thermal therapy and preserves ejaculatory function but produces delayed improvement over months. Prostatic artery embolization (PAE) is an emerging option for large prostates in poor surgical candidates.

Acute Urinary Retention

Acute urinary retention is the inability to void. Initial management is Foley catheter placement (16-18 Fr). A trial without catheter is attempted after 1-3 days of catheter drainage with an alpha blocker. Predictors of successful trial include age under 65, post-void residual under 1 L, retention for less than 24 hours, and no neurologic disease.

Prostatitis

The NIH classification divides prostatitis into four categories. Category I is acute bacterial prostatitis (2-5% of cases), presenting with acute UTI symptoms and fever. Category II is chronic bacterial prostatitis (5-10%), characterized by recurrent UTIs with the same organism. Category III is chronic prostatitis/chronic pelvic pain syndrome (60-80%): IIIA is inflammatory (white blood cells in expressed prostatic secretions) and IIIB is non-inflammatory. Category IV is asymptomatic inflammatory prostatitis (10-15%), found incidentally on biopsy or semen analysis.

Acute Bacterial Prostatitis

Symptoms include dysuria, frequency, urgency, fever, chills, malaise, perineal or pelvic pain, and acute urinary retention. DRE reveals a tender, swollen, warm prostate — examination should be gentle to avoid inducing bacteremia. The most common pathogen is E. coli, followed by Klebsiella, Proteus, Pseudomonas, and Enterococcus. Treatment is empiric antibiotics: a fluoroquinolone (ciprofloxacin, levofloxacin), TMP-SMX, or a third-generation cephalosporin, adjusted based on culture results, for 4-6 weeks. Hospitalization is indicated for sepsis, high fever, inability to tolerate oral medications, or urinary retention.

Chronic Bacterial Prostatitis

Recurrent UTIs with the same pathogen and chronic pelvic pain characterize this condition. Diagnosis is confirmed by positive culture of expressed prostatic secretions or post-massage urine. Treatment is a fluoroquinolone for 4-6 weeks, or TMP-SMX for 6-12 weeks if resistant. Refractory cases may require prostatic massage or transurethral resection to remove infected foci.

Chronic Prostatitis/Chronic Pelvic Pain Syndrome

This condition involves pelvic, perineal, or genital pain for more than 3 months with variable voiding symptoms and sexual dysfunction, without documented UTI. Etiology is multifactorial: possible infection trigger, inflammation, neuromuscular dysfunction, pelvic floor tension, and psychological factors. Treatment is multimodal. Alpha blockers provide moderate symptom improvement. A trial of antibiotics (4-6 weeks) is controversial but may help if occult infection is present. NSAIDs, phytotherapy (quercetin, pollen extract), pelvic floor physical therapy (myofascial release, trigger point therapy, biofeedback), neuromodulators (amitriptyline, gabapentin, pregabalin), and psychological approaches (CBT, stress reduction) all play a role.

ⓘ Information

Pelvic floor physical therapy has emerged as one of the most effective treatments for chronic pelvic pain syndrome. Many men with CPPS have hypertonic pelvic floor muscles — muscles that are chronically tight and tender. A skilled pelvic floor physical therapist uses myofascial release, trigger point dry needling, biofeedback, and relaxation techniques. Patients learn to identify and release pelvic floor tension. Studies report 60-80% improvement in pain scores. This therapy is underutilized because many providers are unaware of it or do not refer. Patients should ask their urologist for a referral to a pelvic floor physical therapist who treats men.

Prostate Cancer

Prostate cancer is the most common cancer in men (excluding skin cancer), with a lifetime risk of 1 in 8. Median age at diagnosis is 66. The 5-year survival for localized disease exceeds 99%, but metastatic disease has a 5-year survival of 32%. African American men have 1.7 times the incidence and 2.1 times the mortality of white men.

Risk Factors

Age is the strongest risk factor — prostate cancer is rare under 40 and 60% are diagnosed after 65. African American race carries the highest incidence globally. Family history in a first-degree relative increases risk 2-3 fold. BRCA2 mutation carriers have 3-5 times the risk, and Lynch syndrome confers 2-3 times the risk. Obesity and smoking are associated with more aggressive disease.

PSA Screening

The decision to screen with PSA is individualized. The USPSTF recommends shared decision-making for men ages 55-69 (C recommendation) and recommends against screening over age 70 (D). Other organizations vary: the AUA recommends shared decision-making at ages 55-69, with consideration starting at age 40-54 for high-risk men (African American, family history). The NCCN recommends a baseline PSA at age 45, with screening starting at 40-45 for high-risk groups.

PSA levels are interpreted in context. A PSA under 2.5 ng/mL is generally low risk for men under 50. The gray zone of 4-10 ng/mL carries a 20-30% probability of cancer. Levels over 10 ng/mL indicate 50-70% probability, and over 20 ng/mL suggests advanced disease. PSA derivatives such as PSA density, PSA velocity, free PSA ratio, and PSA doubling time help refine risk assessment.

Gleason Score and Grade Groups

The Gleason score is the sum of the two most common histologic patterns (each graded 1-5). Grade Group 1 corresponds to Gleason 6 (3+3) — very low to low risk. Grade Group 2 is Gleason 7 (3+4) — favorable intermediate. Grade Group 3 is Gleason 7 (4+3) — unfavorable intermediate. Grade Group 4 is Gleason 8 — high risk. Grade Group 5 is Gleason 9-10 — very high risk.

⚠ Caution

The controversy over PSA screening has largely resolved into a consensus of shared decision-making. For men aged 55-69, the decision should be individualized based on values and preferences. The risk of overdiagnosis (identifying cancers that would never have caused harm) is balanced against the potential to detect high-risk cancers early. A single PSA test carries limitations, but the availability of additional tools (free PSA, 4Kscore, SelectMDx, multiparametric MRI, and genomic classifiers) allows for more nuanced risk assessment. The key is an informed discussion between the patient and clinician, not a blanket policy of screening or not screening.

Treatment by Stage

For very low and low-risk disease, active surveillance is the preferred approach — monitoring with serial PSA, DRE, and periodic biopsies, with treatment reserved for progression. This avoids overtreatment of indolent cancers.

For intermediate and high-risk localized disease, options include radical prostatectomy (open, laparoscopic, or robotic) or radiation therapy. Radical prostatectomy carries risks of incontinence (5-15% at 1 year) and erectile dysfunction (50-80%). External beam radiation (IMRT/IGRT), brachytherapy (seed implant), and stereotactic body radiation are alternatives with different side-effect profiles.

For metastatic disease, the mainstay is androgen deprivation therapy (ADT) — LHRH agonists (leuprolide, goserelin, triptorelin), LHRH antagonists (degarelix, relugolix), or anti-androgens (bicalutamide, enzalutamide, apalutamide, darolutamide). ADT is often combined with abiraterone/prednisone or docetaxel chemotherapy for more advanced disease. PARP inhibitors (olaparib, rucaparib) are options for patients with BRCA1/2 or ATM mutations. Lu-177 PSMA-617 (Pluvicto) is a radiopharmaceutical therapy for PSMA-positive metastatic castration-resistant prostate cancer.

Summary

Prostate health encompasses three common conditions. BPH causes bothersome urinary symptoms and is treated with alpha blockers, 5-ARIs, combination therapy, or surgery depending on symptom severity and prostate size. Prostatitis ranges from acute bacterial infection requiring antibiotics to chronic pelvic pain syndrome requiring multimodal therapy including pelvic floor physical therapy. Prostate cancer screening through shared decision-making identifies disease at a stage where treatment is highly effective, with active surveillance preferred for low-risk disease. Age, race, and family history are the most important risk factors.